Zymeworks and Merck collaborate on "bispecific" antibodies

08/29/2011 | Xconomy

Canada's Zymeworks agreed to partner with Merck & Co. to develop "bispecific" antibody drugs for cancer and autoimmune conditions. The deal entitles Zymeworks to as much as $187 million in upfront and milestone fees, plus tiered royalties. Merck will gain exclusive global rights to market resulting therapies.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC